A Phase 3 Study of Guselkumab in Subjects with Active Psoriatic Arthritis

Registry ID

EUCTR2016-001163-37

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Janssen-Cilag International N.V.

Start date

2017-07-25

Completion date

2019-11-18

Last update

2026-08-16

Conditions

• Active Psoriatic Arthritis

Summary

The primary objective of this study is to evaluate the efficacy of guselkumab treatment in subjects with active PsA by assessing the reduction in signs and symptoms of PsA.

Locations

• , , Germany
• , , Poland
• , , Spain
• , , Czechia
• , , Hungary

Related clinical trials

• Korean Post-marketing Surveillance for Xeljanz XR

View on source registry